NeuroOne Medical Technologies Corporation Appoints Edward Andrle as New Board Member Eden Prairie, Minn.

NeuroOne Medical Technologies Corporation

Appoints Edward Andrle as New Board Member

Eden Prairie, Minn., February 24, 2020

NeuroOne Medical Technologies Corporation

(OTCQB: NMTC), a medical technology company focused on improving surgical care options and outcomes for patients suffering from

neurological disorders, announced today the appointment of Edward Andrle to the Company's Board of Directors.

Mr. Andrle most recently served as the

General Manager of the Neuromodulation franchise at LivaNova PLC (NASDAQ: LIVN), a publicly traded medical device company. Prior

to LivaNova, Mr. Andrle served as Sorin's Vice-President of Strategy & Business Development. He also has previously

held executive positions with Boston Scientific and Baxter, leading large product portfolios in both neuromodulation and cardiac

devices. Mr. Andrle has been a co-founder and CEO for several early stage medical device companies in both the neuromodulation

and cardiovascular industries. In addition, he has also served on the board of many privately held medical device companies. Mr.

Andrle received his MBA from Stanford Graduate School of Business and his B.S. in Chemical Engineering from the University of

President and CEO of NeuroOne, commented, "We are pleased to have Mr. Andrle join our board of directors. He brings

decades of experience leading neuromodulation and cardiovascular companies in senior management roles such as: CEO, business development,

portfolio management, venture capital advisor, and extensive experience in negotiating and acquiring new technologies, which we

believe will be very helpful to our future corporate strategy and operations."

"I am thrilled to be joining NeuroOne's

Board of Directors," Mr. Andrle said. "Given my experience in the neuromodulation industry I am excited about the

potential that NeuroOne's technology can offer to patients and physicians and look forward to contributing to the Company's

Technologies Corporation is a developmental stage company committed to providing minimally invasive and hi-definition solutions

for EEG recording, brain stimulation and ablation solutions for patients suffering from Epilepsy, Parkinson's Disease, Essential

Tremors and other related neurological disorders that may improve patient outcomes and reduce procedural costs. For additional

information, go to www.neurooneinc.com.

may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section

21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information contained in

this presentation may be a forward-looking statement that reflects the Company's current views about future events and are

subject to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance

or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some

cases, you can identify forward-looking statements by the words "may," "might," "will," "could,"

"would," "should," "expect," "intend," "plan," "objective,"

"anticipate," "believe," "estimate," "predict," "project," "potential,"

"target," "seek," "contemplate," "continue" and "ongoing," or the

negative of these terms, or other comparable terminology intended to identify statements about the future. Forward-looking statements

may include statements regarding the Company's regulatory submissions, potential regulatory approval, commercialization

of the technology, business strategy, market size, potential growth opportunities, plans for product applications and product

development, future operations, future efficiencies, and other financial and operating information. Although the Company believes

that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination

of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Our actual future

results may be materially different from what we expect due to factors largely outside our control, including our ability to raise

additional funds, uncertainties inherent in the development process of our technology, changes in regulatory requirements or decisions

of regulatory authorities, the size and growth potential of the markets for our technology, our ability to serve those markets,

the rate and degree of market acceptance of our products, clinical trial patient enrollment, the results of clinical trials, future

competition, the actions of third-party clinical research organizations, suppliers and manufacturers, our ability to protect our

intellectual property rights and other risks, uncertainties and assumptions, including those described under the heading "Risk

Factors" in our filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the

date of this press release and the Company undertakes no obligation to revise or update any forward-looking statements for any

reason, even if new information becomes available in the future.

Investor Relations Contact:

Sr. Director of Marketing

NeuroOne Medical Technologies Corporation

"Caution: Federal law restricts

this device to sale by or on the order of a physician"